T0	KEYPHRASE-NOTYPES 6 20	identification
T1	KEYPHRASE-NOTYPES 30 38	children
T2	KEYPHRASE-NOTYPES 42 50	low risk
T3	KEYPHRASE-NOTYPES 55 70	Lyme meningitis
T4	KEYPHRASE-NOTYPES 87 108	outpatient management
T5	KEYPHRASE-NOTYPES 124 145	Lyme serology results
T6	KEYPHRASE-NOTYPES 147 163	Previous studies
T7	KEYPHRASE-NOTYPES 186 208	laboratory differences
T8	KEYPHRASE-NOTYPES 217 225	children
T9	KEYPHRASE-NOTYPES 231 246	Lyme meningitis
T10	KEYPHRASE-NOTYPES 254 265	forms
T11	KEYPHRASE-NOTYPES 269 287	aseptic meningitis
T12	KEYPHRASE-NOTYPES 311 332	single-center studies
T13	KEYPHRASE-NOTYPES 349 366	small sample size
T14	KEYPHRASE-NOTYPES 378 388	validation
T15	KEYPHRASE-NOTYPES 402 422	retrospective cohort
T16	KEYPHRASE-NOTYPES 430 438	children
T17	KEYPHRASE-NOTYPES 453 468	Lyme meningitis
T18	KEYPHRASE-NOTYPES 470 475	Avery
T19	KEYPHRASE-NOTYPES 497 537	Lyme meningitis clinical prediction rule
T20	KEYPHRASE-NOTYPES 555 562	factors
T21	KEYPHRASE-NOTYPES 564 572	duration
T22	KEYPHRASE-NOTYPES 576 584	headache
T23	KEYPHRASE-NOTYPES 586 594	presence
T24	KEYPHRASE-NOTYPES 598 614	cranial neuritis
T25	KEYPHRASE-NOTYPES 620 630	percentage
T26	KEYPHRASE-NOTYPES 634 655	CSF mononuclear cells
T27	KEYPHRASE-NOTYPES 662 680	prospective cohort
T28	KEYPHRASE-NOTYPES 687 695	children
T29	KEYPHRASE-NOTYPES 710 725	Lyme meningitis
T30	KEYPHRASE-NOTYPES 731 742	Avery model
T31	KEYPHRASE-NOTYPES 770 783	investigators
T32	KEYPHRASE-NOTYPES 796 810	simplification
T33	KEYPHRASE-NOTYPES 823 860	complicated Avery regression equation
T34	KEYPHRASE-NOTYPES 873 877	Rule
T35	KEYPHRASE-NOTYPES 881 884	79s
T36	KEYPHRASE-NOTYPES 892 900	Children
T37	KEYPHRASE-NOTYPES 932 940	criteria
T38	KEYPHRASE-NOTYPES 960 968	low risk
T39	KEYPHRASE-NOTYPES 973 988	Lyme meningitis
T40	KEYPHRASE-NOTYPES 993 997	days
T41	KEYPHRASE-NOTYPES 1001 1009	headache
T42	KEYPHRASE-NOTYPES 1016 1037	CSF mononuclear cells
T43	KEYPHRASE-NOTYPES 1043 1050	absence
T44	KEYPHRASE-NOTYPES 1073 1092	cranial nerve palsy
